PSC
VRTX icon

Piper Sandler & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Piper Sandler & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,825
Closed -$481K – 26
2015
Q4 		$481K Buy
+3,825
New +$462K 1.22% 11

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Piper Sandler & Co's VRTX Position: Q1 2016 in Review

Piper Sandler & Co sold out of Vertex Pharmaceuticals (VRTX) in Q1 2016, closing a stake of 3,825 shares — an estimated $481K sold.

Piper Sandler & Co first reported a position in VRTX in Q4 2015 and held it in 1 quarter. The position peaked at $481K in Q4 2015. 502 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

  • Piper Sandler & Co reported no remaining Vertex Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Piper Sandler & Co sold 3,825 Vertex Pharmaceuticals shares in Q1 2016, an estimated $481K.
  • Piper Sandler & Co first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Piper Sandler & Co's Vertex Pharmaceuticals position peaked at $481K in Q4 2015.
  • 502 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on Piper Sandler & Co's 13F filing for Q1 2016, filed 16 May 2016.